临床基因组学和实验治疗学-猫眼课题宝

临床基因组学和实验治疗学

批准号：

9362209

负责人：

Falk Lohoff

金额：

$276.35万

依托单位：

NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

依托单位国家：

美国

项目类别：

财政年份：

资助国家：

美国

项目状态：

未结题

起止时间：

至

来源：

https://reporter.nih.gov/project-details/9362209

关键词：

Affect Affective Anxiety Disorders Area Biological Markers Clinical Clinical Research DNA Sequence Dopamine Emotions Epigenetic Process Fright Functional Imaging Functional disorder Genetic Genomics Genotype Human Individual Differences Intervention Investigational Therapies Methods Molecular Neurobiology Neurons Other Genetics Pharmacogenetics Pharmacological Treatment Phase Post-Traumatic Stress Disorders Process Proteomics Regulation Research Risk Signal Transduction Subgroup Translating Treatment outcome Work addiction alcohol use disorder base dopamine transporter emotion regulation genetic approach genome-wide human population genetics imaging genetics interest molecular marker neurobiological mechanism next generation novel therapeutics pre-clinical precision medicine preclinical study problem drinker research study transcriptome sequencing treatment response

项目摘要

项目成果

Falk Lohoff的其他基金

相似基金

相关文献

中文摘要

翻译

临床基因组学和实验治疗学（SCGET） 1.开展临床前研究和转化临床研究，重点关注基因组学与酒精使用障碍的病理生理学和治疗有关的表观遗传学，上瘾 2.临床前工作的重点是确定参与成瘾的分子机制，利用广泛的方法，包括人类群体遗传学、全基因组基因分型方法，下一代DNA和RNA测序，以及表观遗传/蛋白质组学分析。 3.这些发现被转化为使用分子生物标志物的人类临床研究，药物遗传学、表观遗传学和功能成像遗传学方法。 4.临床研究包括早期的1期/2期概念验证研究，通过分子生物标志物分析指导的新疗法。

英文摘要

Section on Clinical Genomics and Experimental Therapeutics (SCGET) 1. Conducts pre-clinical studies and translational clinical studies with focus on genomics and epigenetics related to the pathophysiology and treatment of alcohol use disorders and addictions. 2. Pre-clinical work focuses on identifying molecular mechanisms involved in addictions, utilizing a wide array of methods including human population genetics, genome wide genotyping approaches, next-generation DNA and RNA sequencing, and epigenetic/proteomic profiling. 3. Findings are translated into human clinical studies using molecular biomarker, pharmacogenetic, epigenetic and functional imaging genetic approaches. 4. Clinical studies include early phase 1 / phase 2 proof-of-concept studies of experimental novel therapeutics guided by molecular biomarker profiling.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文